DNMT3A and myeloid leukemia: Given that the human DNMT3A R882H (mouse R878H) is a driver mutation for clonal hematopoiesis and one of the major risk factors for myeloid leukemia progression [1–3, 6], it is of great importance to obtain small molecule(s) inhibiting hematopoietic cells carrying DNMT3A R882H.